CLAIMS

What is claimed is:

1. A compound of Formula (I):



Formula (I);

wherein:

R^1 is $-N(R^2)C(O)R^{15}$ or $-N(H)SO_2R^{15}$;

R^2 is H or C_{1-6}alkyl;

R^3 is , , , , , , , , , , , , , , , or ;

A is N or C(H);

X is -O-, $-N(R^{16})-$, or $-CH_2N(R^{16})CH_2-$;

Y is $-CH_2-$ or -C(O)-;

Z is -S-, -O-, or $-N(R^{20})-$;

R^4 is H, halogen, $-OR^7$, C_{1-6}alkyl, C_{1-6}alkyl-OH, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}haloalkyl, $-O-C_{3-8}$cycloalkyl, $-O-C_{3-8}$cycloalkyl-OH, $-N(H)-C_{1-6}$alkyl-CO_2H, $-SO_2R^{17}$, $-CO_2R^8$, $-C(O)NR^8R^9$,

C_{3-8}cycloalkyl, C_{2-9}heterocycloalkyl, -C_{1-6}alkyl-C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, wherein C_{3-8}cycloalkyl, C_{2-9}heterocycloalkyl, -C_{1-6}alkyl-C_{2-9}heterocycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl are optionally substituted with 1 or 2 R^{14};

R^5 is H, -CN, halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}haloalkoxy, or phenyl;

R^6 is H, halogen, or C_{1-6}alkyl;

R^7 is H, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-8}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, or C_{1-9}heteroaryl, wherein C_{2-9}heterocycloalkyl, C_{6-10}aryl, or C_{1-9}heteroaryl are optionally substituted with 1 or 2 R^{14};

each R^8 and each R^9 are independently selected from H and C_{1-6}alkyl; or R^8 and R^9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;

R^{10} is -O-C_{1-6}haloalkyl, -O-C_{1-6}alkyl-CO_2H, -O-C_{3-8}cycloalkyl, -O-C_{3-8}cycloalkyl-CO_2H, -N(H)-C_{1-6}alkyl-CO_2H, or -SO_2R^{17};

R^{12} is H, halogen, or C_{1-6}alkyl;

R^{13} is H or C_{1-6}alkyl;

each R^{14} is independently selected from halogen, -OH, oxo, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6}alkoxy, -C_{1-6}alkyl-OH, C_{3-8}cycloalkyl, -CO_2R^8, -C(O)NR^8R^9, -C(O)-C_{1-6}alkyl, -C(O)-C_{1-6}alkyl-OH, -SO_2-C_{1-6}alkyl, -N(R^8)SO_2-C_{1-6}alkyl, and -N(R^8)C(O)-C_{1-6}alkyl;

R^{15} is C_{1-6}alkyl or C_{3-8}cycloalkyl;

R^{16} is H, C_{1-6}alkyl, -C(O)-C_{1-6}alkyl, or -CH_2CO_2H;

R^{17} is C_{1-6}alkyl or C_{3-8}cycloalkyl;

R^{18} and R^{19} are independently selected from H and C_{1-6}alkyl, wherein R^{18} and R^{19} are not both H;

R^{20} is H or C_{1-6}alkyl;

v is 0 or 1;

n is 0 or 1;

m is 0 or 1;

p is 0, 1, or 2;

q is 0, 1, or 2; and

w is 1 or 2;

or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^3 is .
3. The compound of claim 2, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, p is 1, and w is 1.
4. The compound of any one of claims 1-3, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein A is C(H).
5. The compound of any one of claims 1-4, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein Y is $-CH_2-$.
6. The compound of any one of claims 1-5, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^6 is H.
7. The compound of any one of claims 1-6, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^{13} is H.
8. The compound of any one of claims 1-7, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^{12} is H.
9. The compound of any one of claims 1-8, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is halogen, $-OR^7$, C_{1-6}alkyl-OH, -N(H)-C_{1-6}alkyl-CO_2H, C_{2-6}alkynyl, C_{1-6}haloalkyl, $-CO_2R^8$, $-C(O)NR^8R^9$, C_{3-8}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, or C_{1-9}heteroaryl, wherein C_{3-8}cycloalkyl, C_{2-9}heterocycloalkyl, C_{6-10}aryl, or C_{1-9}heteroaryl are optionally substituted with 1 or 2 R^{14}.
10. The compound of any one of claims 1-9, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is halogen, $-OR^7$, -N(H)-C_{1-6}alkyl-CO_2H, C_{1-6}haloalkyl, $-C(O)NR^8R^9$, C_{3-8}cycloalkyl, C_{2-9}heterocycloalkyl, or C_{1-9}heteroaryl, wherein C_{2-9}heterocycloalkyl or C_{1-9}heteroaryl are optionally substituted with 1 or 2 R^{14}.
11. The compound of any one of claims 1-10, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is C_{1-6}haloalkyl.
12. The compound of claim 11, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is $-CF_3$.

13. The compound of any one of claims 1-12, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is -N(H)-C_{1-6}alkyl-CO_2H.
14. The compound of any one of claims 1-13, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^4 is -$C(O)NH_2$.
15. The compound of any one of claims 1-14, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^5 is H, -CN, halogen, C_{1-6}alkyl, C_{1-6}haloalkyl, or C_{1-6}haloalkoxy.
16. The compound of claim 15, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^5 is C_{1-6}haloalkyl.
17. The compound of claim 16, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^5 is -CF_3.
18. The compound of any one of claims 1-17, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^1 is -$N(R^2)C(O)R^{15}$.
19. The compound of claim 18, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^2 is H.
20. The compound of claim 18, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^{15} is -CH_3.
21. A compound selected from:


,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

;

,

,

,

,

,

,

,

,

,

,

,

,

,

,

;


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

;


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

;


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

;

or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a compound of any one of claims 1-21, or a solvate, hydrate, tautomer, *N*-oxide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
23. Use of a compound according to any one of claims 1 – 21 in the preparation of a medicament for treating of condition.
24. Use of a compound according to any one of claims 1-21 in the preparation of a medicament for the treatment of migraine.